A carregar...
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
Vorapaxar (ZONTIVITY™, formerly known as SCH 530348) is a specific, orally active antagonist of the protease-activated receptor-1 (PAR-1) on platelets. It inhibits thrombin-induced platelet activation by binding to the ectodomain of PAR-1. After animal studies and Phase II studies showed that vorapa...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4529257/ https://ncbi.nlm.nih.gov/pubmed/26346960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S55469 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|